Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

The person is using 1mg of finasteride daily, 2mg of minoxidil, and weekly dermarolling with a 1mm needle. They sometimes use topical minoxidil as well.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

A user with diffuse thinning experienced no hair regrowth with finasteride or Avodart but slowed hair loss with Avodart. They are considering trying Minoxidil and are seeking advice on whether to use foam or liquid, and if combining it with other treatments could be beneficial, excluding micro-needling due to scalp irritation concerns.

A user shared their 3-month progress using oral minoxidil, finasteride, and topical minoxidil for hair loss. Another user commented on the significant improvement, hoping for similar results.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The conversation discusses converting liquid minoxidil into a foam version to save money. The user is exploring if a foam sprayer can achieve this or if additional ingredients are needed.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

A user shared progress pictures after 3 months on oral minoxidil (2.5mg) and oral finasteride (1mg), noting initial side effects with higher finasteride doses. They report no issues after reducing the finasteride dose to 1mg.

The user shared progress pictures showing significant hair regrowth after three months using 5% foam minoxidil, 0.3% dutasteride, microneedling, pumpkin seed oil, and rosemary oil. The user reported no side effects and chose topical treatments to avoid them.

Stemoxydine may work synergistically with minoxidil and finasteride for hair growth, but its effectiveness is debated, with some users experiencing minimal results and concerns about cost. Users suggest sticking to proven treatments like minoxidil and finasteride, while considering stemoxydine as an additional option.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.

Hair loss treatments, such as minoxidil and finasteride, being replaced by verteporfin, with humorous responses.

The user is using 5% minoxidil foam twice daily and 1mg finasteride nightly for hair loss, and has seen positive results in 3 months. They plan to continue the treatment indefinitely as it provides reassurance against hair loss.

A user shared their 3-month progress using a topical solution containing 0.3% finasteride, 7% minoxidil, 2.2% ketoconazole, and 0.2% biotin, reporting improvements in thinning areas. Another user mentioned using oral finasteride, oral minoxidil, dutasteride, and minoxidil foam, discussing costs and side effects.

A user shared 3-month progress pictures using 1mg finasteride daily, reporting no side effects and planning to add oral minoxidil. Replies praised the results and questioned the need to add minoxidil.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The user is experiencing hair regrowth using topical 0.3% finasteride and 6% minoxidil, with no side effects noted. They are considering switching to oral treatments if progress stalls, but are currently satisfied with the results.

The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.